SCHEMBL7121233

SCHEMBL7121233

CC(C)c1c(OCC2CCC2)c2cc(Cl)ccc2[nH]c1=O

nearest known ligand 0.46

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
SIRT1 Q96EB6 1/20 0.42
TRPV1 Q8NER1 1/20 0.40
PARP15 Q460N3 2/20 0.40
PARP10 Q53GL7 2/20 0.40
LMNA P02545 1/20 0.40
PDE2A O00408 1/20 0.39
SLC6A4 P31645 1/20 0.39
HTR6 P50406 1/20 0.39
CYP2D6 P10635 1/20 0.39
OPRM1 P35372 1/20 0.38
OPRD1 P41143 1/20 0.38
OPRK1 P41145 1/20 0.38
OPRL1 P41146 1/20 0.38
CSF1R P07333 1/20 0.37
MEN1 O00255 1/20 0.37
ALDH1A1 P00352 1/20 0.37
MAPT P10636 1/20 0.37
KMT2A Q03164 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7114952 0.86 PARP15 (0.40) TRPV1PARP15PARP10PDE2ASLC6A4
SCHEMBL7123048 0.84 LMNA (0.41) TRPV1PARP15PARP10LMNAPDE2A
SCHEMBL7116736 0.82 SIRT1 (0.42) SIRT1PARP15PARP10LMNAPDE2A
SCHEMBL7114050 0.80 PDE9A (0.44) SIRT1LMNACSF1R
SCHEMBL7118669 0.80 KDM4C (0.47) TRPV1PARP15PARP10PDE2ACYP2D6
SCHEMBL7115575 0.79 SIRT1 (0.42) SIRT1PARP15PARP10PDE2ASLC6A4
SCHEMBL7115553 0.78 PARP15 (0.37) PARP15PARP10PDE2ASLC6A4ALDH1A1
SCHEMBL7125974 0.77 SIRT1 (0.44) SIRT1PDE2ACSF1RMEN1ALDH1A1
SCHEMBL7116752 0.75 SIRT1 (0.40) SIRT1LMNACSF1RMEN1ALDH1A1
SCHEMBL936013 0.74 CYP2D6 (0.46) PDE2ASLC6A4CYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030069271-A1 Quinolone compounds for use in treating viral infections SMITHKLINE BEECHAM CORPORATION 2003-04-10 US claimed
EP-1244629-A2 QUINOLONE COMPOUNDS FOR USE IN TREATING VIRAL INFECTIONS GLAXO GROUP LIMITED (GB) 2002-10-02 EP claimed
WO-2001046150-A2 QUINOLONE COMPOUNDS FOR USE IN TREATING VIRAL INFECTIONS GLAXO GROUP LIMITED (GB) 2001-06-28 WO claimed
US-20030069271-A1 Quinolone compounds for use in treating viral infections SMITHKLINE BEECHAM CORPORATION 2003-04-10 US disclosed
EP-1244629-A2 QUINOLONE COMPOUNDS FOR USE IN TREATING VIRAL INFECTIONS GLAXO GROUP LIMITED (GB) 2002-10-02 EP disclosed
WO-2001046150-A2 QUINOLONE COMPOUNDS FOR USE IN TREATING VIRAL INFECTIONS GLAXO GROUP LIMITED (GB) 2001-06-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030069271-A1 Quinolone compounds for use in treating viral infections IRF3, MAVS, NQO2 SIRT1 722/4885TRPV1 2228/4885PARP15 616/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.